Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Promote Elimination of Films from Imaging Diagnosis
November 12, 2007
- 11 Generics Receive NHI Price Listing in the 1st Biannual Listing
November 12, 2007
- Pfizer Japan Begins Restructuring to Spur Simultaneous Global Development
November 12, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 12, 2007
- BUSINESS NEWS IN BRIEF
November 12, 2007
- STPO PRESS／Prasugrel Significantly Reduces Risk of Serious CV Events Compared to Clopidogrel
November 12, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2007
- TOPICS 2 articles
November 12, 2007
- Nadesiko Society Provides Support for Female MRs: Janssen
November 12, 2007
- Merck Serono to Expand Business in Japan in Earnest
November 12, 2007
- R&D NEWS IN BRIEF
November 12, 2007
- NEW PRODUCTS／Janssen: Concerta Tablet for ADHD
November 12, 2007
- Council Recommends Early Domestic Development of 4 Drugs
November 12, 2007
- Sales of Spiriva to Reach \12.6 Bil. in 2007: NBI
November 12, 2007
- Eisai to File an NDA for E2007 for Parkinson's Disease in FY2008
November 12, 2007
- SSP: Ordinary Profits Up 17% by Optimizing Operation Efficiency
November 12, 2007
- Gastric Cancer GL Stress Use of TS-1 for Inoperable Patients
November 5, 2007
- Kirin HD-Kyowa Hakko Deal Beneficial for Kirin HD, Neutral for Kyowa Hakko's Shareholders: DIR Report
November 5, 2007
- Defensive Factor Enhancing Agents Not Recommended after Endoscopic Therapy
November 5, 2007
- Mr Sekiguchi Explains PhRMA's Stance Regarding NHI Pricing
November 5, 2007
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…